Literature DB >> 12845

Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo.

G C White, H R Roberts, H S Kingdon, R L Lundblad.   

Abstract

Factors affecting the coagulant activity of two different prothrombin complex concentrates have been investigated using a sensitive in vitro assay developed in this laboratory. One concentrate contained substantial amounts of potentially thrombogenic material, while the other, which was deliberately fortified with antithrombin III and heparin during production, was judged to be relatively nonthrombogenic. The coagulant activity of the thrombogenic concentrate has been partially identified and was due largely to the presence of coagulation factos IXa and Xa. Neither concentrate contained detectable thrombin. However, after incubation with calcium or various polyamines, large amounts of additional coagulant material, including thrombin, appeared. Heparin and antithrombin III not only neutralized the thrombogenic materials present in the thrombogenic concentrate, but also inhibited the de novo generation of coagulant enzymes during incubation with calcium. The implication of these studies on the preparation of prothrombin complex concentrates and on host susceptibility to thrombosis during the clinical use of these concentrates is discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 12845

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation.

Authors:  A R Giles; M E Nesheim; K G Mann
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

2.  The female carrier of haemophilia--a problem for the anaesthetist.

Authors:  M J Inwood; D B Meltzer
Journal:  Can Anaesth Soc J       Date:  1978-07

Review 3.  Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature.

Authors:  Eric M Bershad; Jose I Suarez
Journal:  Neurocrit Care       Date:  2010-06       Impact factor: 3.210

4.  Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs.

Authors:  J H Axelrod; M S Read; K M Brinkhous; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

5.  Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa.

Authors:  Pablo Rendo; Janice Lamb; Lynne Smith; Joanne Fuiman; Joan M Korth-Bradley
Journal:  Blood Coagul Fibrinolysis       Date:  2018-01       Impact factor: 1.276

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.